IP Library › Granted Patent US 7,601,728
Granted Patent B2
US 7,601,728 · App. 12/127,858 · Granted Oct 13, 2009

Bicyclic pyrrole derivatives

Assignee: Dainippon Sumitomo Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,601,728
App. No.
12/127,858
Granted
Oct 13, 2009
Kind
B2
Abstract

Compounds represented by the general formula (I), prodrugs thereof, or pharmaceutically acceptable salts of both are provided as compounds which have high DPP-IV inhibiting activity and are improved in safety, toxicity and so on: (I) wherein the solid line and dotted line between A 1 and A 2 represents a double bond (A 1 ═A 2 ) or the like; A 1 is C(R 4 ) or the like; A 2 is nitrogen atom or the like; R 1 is hydrogen atom, optionally substituted alkly group, or the like; R 2 is hydrogen atom, optionally substituted alkyl group, or the like; R 3 is hydrogen atom, halogen atom, or the like; R 4 is hydrogen atom, hydroxyl, halogen atom, or the like; and Y is a group represented by the general formula (A) or the like; (A) [wherein m1 is 0, 1, 2 or 3; and the group (A) may be freed from R 6 or substituted with one or two R 6 's which are each independently halogen atom or the like.]

Claims (5)

1. A compound represented by the formula:

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 , wherein the pharmaceutically acceptable sale is hydrochloride.

3. A method for treating diabetes comprising administering an effective amount of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1 to a patient who needs the treatment.

4. A method for treating diabetes comprising administering an effective amount of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 2 to a patient who needs the treatment.

Priority Claims (1)
JP 2004-372772 · Dec 24, 2004 · national
Continuity (2)
Continuation 1172203700
Related Publication 20090149483A1 · Jun 11, 2009